Dr. Stiles is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 East 210th Street
Bronx, NY 10467Phone+1 718-920-5732
Summary
- Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic & Vascular Surgery at Montefiore-Einstein, and the Associate Director for Surgical Services in the Montefiore-Einstein Cancer Center. Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.
After earning his Bachelor of Arts in 1994 at the University of Virginia, Dr. Stiles continued at UVA, earning his Doctor of Medicine in 1999. He conducted his training in general surgery at the University of Virginia Health System. From 2001 to 2003, Dr. Stiles served as a surgical research fellow at Memorial Sloan-Kettering Cancer Center before returning to the University of Virginia Health System to complete his surgical residency. Dr. Stiles completed a cardiothoracic surgery residency at NewYork-Presbyterian Hospital-Weill Cornell and Memorial Sloan-Kettering Cancer Center in 2008. Dr. Stiles joined the faculty at NewYork-Presbyterian Hospital-Weill Cornell before being recruited to Montefiore-Einstein in 2021.
Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. Dr. Stiles is highly active in the lung cancer care community, having lost his own father to lung cancer in 2005. He is committed to raising money for lung cancer research, serving as chair of the Lung Cancer Research Foundation since 2017.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Thoracic Surgery, 2006 - 2008
- University of Virginia Medical CenterResidency, Surgery, 1999 - 2006
- University of Virginia School of MedicineClass of 1999
Certifications & Licensure
- FL State Medical License 2020 - Present
- CT State Medical License 2024 - 2025
- NY State Medical License 2006 - 2025
- VA State Medical License 1999 - 2006
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Fellow (FACS) American College of Surgeons
Clinical Trials
- An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer Start of enrollment: 2023 Jan 25
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 650 citationsThe lung microenvironment: an important regulator of tumour growth and metastasisNasser K. Altorki, Geoffrey J. Markowitz, Dingcheng Gao, Jeffrey L. Port, Ashish Saxena
Nature Reviews. Cancer. 2019-01-01 - 564 citationsThoracoscopic lobectomy is associated with lower morbidity than open lobectomy: A propensity-matched analysis from the STS databaseSubroto Paul, Nasser K. Altorki, Shubin Sheng, Paul C. Lee, David H. Harpole
The Journal of Thoracic and Cardiovascular Surgery. 2010-02-01 - 163 citationsNeoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trialNasser K. Altorki, Timothy E. McGraw, Alain C. Borczuk, Ashish Saxena, Jeffrey L. Port
The Lancet. Oncology. 2021-06-01
Authored Content
- Surgeons Will Always Be Needed, No Matter the TechMay 2019
- Surgeons Will Always Be Needed, No Matter the TechMay 2019
- Surgeons Will Always Be Needed, No Matter the TechMay 2019
- How Far Would You Drive to Increase Your Chances of Cancer Survival?February 2019
- A Sea of Presentations, and Those That Are Making WavesOctober 2018
- Study Looks at the “Harms” of Lung Cancer ScreeningMay 2018
- Join now to see all
Press Mentions
- Annabelle Gurwitch to Emcee Lung Cancer Research Foundation GalaSeptember 21st, 2022
- Lung Cancer Research Foundation Creates Scientific Executive CommitteeJuly 11th, 2022
- Brendon Stiles, MD, Joins LUNGevity Scientific Advisory BoardApril 7th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Industry Relationships
- Paid speaker, AstraZeneca, WebMD, Ribon Therapeutics, MedtronicDisclosure: As above2018 - 2019
- Paid speaker, AstraZeneca, WebMD, Ribon Therapeutics, MedtronicDisclosure: As above2018 - 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: